Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

BH3 mimetics are small molecules that mimic BH3-only proteins by binding to and inhibiting the prosurvival members of the Bcl-2 family ... (the majority with follicular lymphoma) received ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.

Sarepta’s flagship Duchenne muscular dystrophy drug Elevidys—which won FDA approval in June 2023—delivered preliminary fourth-quarter and full-year sales of $384.2 million and $820.8 million ...

Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData ... by targeting pro-apoptotic ...

Sonrotoclax is under development for the treatment of relapsed and refractory multiple myeloma, B-cell malignancies such as nodal, extranodal, splenic marginal zone lymphoma ... targeting ...

B-cell lymphoma-2 (BCL-2) protein family members are key to the intrinsic, mitochondrial apoptotic pathway. The inhibition of the BCL-2 family pro-survival proteins, which are frequently overexpressed ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...